Pfizer Inc. $PFE Shares Acquired by Lmcg Investments LLC

Lmcg Investments LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.8% in the second quarter, Holdings Channel.com reports. The firm owned 62,597 shares of the biopharmaceutical company’s stock after acquiring an additional 2,284 shares during the period. Lmcg Investments LLC’s holdings in Pfizer were worth $1,517,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at $27,000. North Capital Inc. bought a new stake in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter valued at about $28,000. Horizon Financial Services LLC acquired a new position in Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Stock Performance

NYSE:PFE opened at $24.81 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The firm’s fifty day simple moving average is $24.86 and its 200 day simple moving average is $24.13. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $141.03 billion, a PE ratio of 13.19, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the business posted $0.60 EPS. Pfizer’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.